Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 2009

View Archived Issues

[123I]MNI-420 shows promise for imaging A2A receptors in the brain

Novel antimalarials reported by the Instituto Nacional de Pesquisas da Amazonia

University of Sydney claims new series of translocator protein ligands

Institut Pasteur, CNRS, INSERM design novel anti-HIV inhibitors

Hong Kong University of Science and Technology describes novel NMDA antagonists

High Point Pharmaceuticals discloses inhibitors of TNF-alpha production and PDE4

Immunoadhesins for human IL-10, a novel approach in cancer immunotherapy

Kyowa Hakko Kirin reports results from first quarter 2009

Clinuvel receives European approval to initiate phase III trial of afamelanotide in EPP

Nuevolution and Novartis sign drug discovery collaboration involving Chemetics

Piramal Life Sciences completes ascending-dose phase I studies of P-1736 in diabetes

FDA accepts Pozen's NDA for Vimovo in OA, RA and AS

Lumavita is granted marketing authorization in Switzerland for pentamycin for vaginitis

CRTH2 receptor antagonists in early development at Argenta Discovery

FDA grants orphan drug designation to Quinazoline-495 for spinal muscular atrophy

FDA Advisory Committee to discuss Genzyme's sNDA for Clolar in adult AML

Effect of rosuvastatin on atrial fibrillation in heart failure patients unclear

PLATO study: reduced cardiovascular events with ticagrelor versus clopidogrel in ACS

Schering-Plough completes recruitment into phase I trial of SCH-900795 for influenza

Delcath Systems enrolls 90% of patients into phase III clinical trial of PHP in metastatic melanoma

Otamixaban superior to unfractionated heparin in non-S-T segment ACS patients

NovaBiotics completes phase I of phase I/IIa clinical trial of Novexatin for fungal nail infection

Studies analyze the benefit of ivabradine in patients with coronary artery disease

Pfizer investigating 5-HT2C agonists for serotonin-related disorders

Antisoma completes enrollment into phase III trial of ASA-404 in NSCLC

FDA accepts for review Johnson & Johnson's complete response letter for ceftobiprole NDA

Shire submits NDA to FDA for velaglucerase alfa and reports results from phase III trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...